Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.

By BioPharma Dive staff • May 13, 2026

A year after Vertex’s big launch, pain drug research faces a pivotal moment

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

By Jacob Bell • May 12, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

By Ben Fidler • May 11, 2026

Biotech layoffs are easing, but is the worst over?

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

By Kelly Bilodeau • May 11, 2026

FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended

Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.

By Ben Fidler • May 8, 2026

Odyssey, on second try, snags $279M in an IPO

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concurrent private deal.

By Gwendolyn Wu • May 7, 2026

Angelini to buy Catalyst in $4B play for rare neuro drugs

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

By Gwendolyn Wu • May 7, 2026

Entrada shares dive as Duchenne results disappoint

While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.

By Kristin Jensen • May 7, 2026

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline

Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020. 

By Delilah Alvarado • May 6, 2026

Avalo shares spike on skin drug data; BioNTech to cut staff

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

By Ben Fidler • May 6, 2026

CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease. 

By Gwendolyn Wu • May 6, 2026

Viridian data lift prospects for thyroid eye disease drug

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

By Delilah Alvarado • May 5, 2026

Vertex earnings get muted investor response

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

By Jacob Bell • May 5, 2026

Cytokinetics heart drug scores in closely watched trial

Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.

By Ben Fidler • May 5, 2026

Cytospire hauls in $83M for a new type of T cell engager

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies. 

By Gwendolyn Wu • May 5, 2026

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

By Delilah Alvarado • May 4, 2026

With $97M, Latus pursues a different kind of Huntington’s gene therapy

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

By Ben Fidler • May 4, 2026

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

By Ben Fidler • May 4, 2026

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.

By Gwendolyn Wu • May 1, 2026

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

By Ben Fidler • May 1, 2026

Moderna sees revenue bump from international COVID vaccine sales

The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.

By Delilah Alvarado • May 1, 2026

Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook

Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.

By Jacob Bell , Jonathan Gardner • May 1, 2026

Two biotechs raise a combined $556M in latest spurt of IPOs

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.

By Gwendolyn Wu • April 30, 2026

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

By Jonathan Gardner • April 30, 2026

UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

News of the submission, which would be the first for UniQure’s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. 

By Delilah Alvarado • April 30, 2026